While rare in sporadic CRC, FGFR2 amplification or fusion and IDH1 R132 mutations occur in intrahepatic cholangiocarcinoma, another inflammation-associated gastrointestinal cancer, and, notably, these oncogenic drivers now have matched FDA-approved targeted therapies41–43 supporting the potential of genomic analysis to alter the landscape of CAC treatment. This evidence concerns the gene IDH1 and colorectal carcinoma.